12/10/2019  8:54:44 PM Chg. +0.07 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
2.69USD +2.48% 492
Turnover: 1,298.44
-Bid Size: - -Ask Size: - 135.54 mill.USD 0.00% -

Business description

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
 

Management board & Supervisory board

CEO
Dr. Elazar Rabbani
Management board
Barry W. Weiner, Dieter Schapfel, James M. O'Brien, Kara Cannon, Paul O’Brien
Supervisory board
Dr. Elazar Rabbani, Barry W. Weiner, Dov Perlysky, Dr. Bruce A. Hanna, Gregory M. Bortz
 

Company data

Name: Enzo Biochem Inc.
Address: 527 Madison Avenue,New York, New York 10022, USA
Phone: +1-212-583-0100
Fax: +1-212-679-7999
E-mail: info@enzo.com
Internet: www.enzo.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 7/31
Free Float: 53.20%
IPO date: -

Investor relations

Name: Steve Anreder
IR phone: +1-212-532-3232
IR Fax: -
IR e-mail: steven.anreder@anreder.com

Main Shareholders

Freefloat
 
53.20%
Evermore Global Advisors LLC
 
9.70%
Blackrock Fund Advisors
 
8.50%
Wellington Management Group LLP
 
8.20%
Renaissance Technologies, LLC
 
6.30%
The Vanguard Group Inc.
 
5.80%
Elazar Rabbani
 
3.90%
Barry W. Weiner
 
2.70%
Dov Perlysky
 
1.70%